Recent achievements showcase company’s leadership as CRO Partner and Employer of Choice in the Asia/Pacific region
BOSTON and DURHAM, N.C., Nov. 29, 2022 (GLOBE NEWSWIRE) — Parexel, one of the world’s largest clinical research organizations (CROs) providing the full range of Phase I to IV clinical development services, today announced recent achievements demonstrating its strength in the Asia/Pacific region as a CRO partner for customers and Employer of Choice for colleagues committed to making a difference for patients. Notable recognitions include earning the 2022 India Workplace Equality Index (IWEI)’s Top Employers Award for the third consecutive year, receiving the 2022-2023 Mercer China Healthiest Workplace Awards for Outstanding Health Practice Award for providing flexible work arrangements to colleagues and marking the company’s 25th anniversary in Japan as one of the longest tenured global CROs in the country.
“Asia/Pacific is a strategically important region of growth and investment for our local and global biotech and pharma customers and for Parexel,” said Peyton Howell, Chief Commercial and Growth Officer. “We’re honored to be recognized consistently for our culture of inclusion and workplace flexibility, and are proud to celebrate 25 years in Japan, a testament to our commitment to and extensive experience in the region.”
Recognized with the 2022 IWEI Top Employer Award in the Bronze category, Parexel was selected for developing inclusive policies and initiating activities that promote LGBT+ inclusion for colleagues. Parexel has received the IWEI Top Employer Award each year since 2020. The IWEI is India’s only comprehensive benchmarking tool for companies to measure their progress on LGBT+ inclusion.
Parexel also received the Outstanding Health Practice Award at the 2022-2023 Mercer China Healthiest Workplace Awards in Shanghai for its flexible work program. By better understanding the specific needs of its colleagues and enabling them to choose the work environment that supports their professional and personal development, Parexel has effectively improved employee engagement and cultivated a greater sense of belonging across its employee base. Launched in 2016 by a leading professional consulting firm in employee health and benefits, the Mercer China Healthiest Workplace Awards spotlight employers in China who provide the healthiest working environments for the sake of improving overall employee health and wellbeing.
As one of the largest and longest-tenured global CROs in Japan, Parexel recently celebrated more than two decades of operations in the country. Parexel Japan has more than 1,000 colleagues across three strategic locations – Kobe, Tokyo and Osaka. With a focus on Patients-First and site relationships, Parexel Japan has conducted nearly 500 clinical trials that have served 170,000 patients, collaborated with over 40,000 site investigators and formed strategic alliances with Kyoto University Hospital, Osaka International Cancer Institute (OICI) and ASird’s STEP (Strategic Translational Action for Empowering Patients) program.
About Parexel
Parexel is among the world’s largest clinical research organizations (CROs), providing the full range of Phase I to IV clinical development services to help life-saving treatments reach patients faster. Leveraging the breadth of our clinical, regulatory and therapeutic expertise, our team of more than 21,000 global professionals works in partnership with biopharmaceutical leaders, emerging innovators and sites to design and deliver clinical trials with patients in mind, increasing access and participation to make clinical research a care option for anyone, anywhere. Our depth of industry knowledge and strong track record gained over the past 40 years is moving the industry forward and advancing clinical research in healthcare’s most complex areas, while our innovation ecosystem offers the best solutions to make every phase of the clinical trial process more efficient. With the people, insight and focus on operational excellence, we work With HeartTM every day to treat patients with dignity and continuously learn from their experiences, so every trial makes a difference. For more information, visit parexel.com and follow us on LinkedIn, Twitter, Facebook and Instagram.
MEDIA
Lori Preuit Dorer
+1 513 496 8121
Lori.Dorer@parexel.com
Danaka Williams
+1 984 298 4207
Danaka.Williams@parexel.com
Marlborough, Massachusetts--(Newsfile Corp. - July 5, 2024) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO), a clinical…
TORONTO and HAIFA, Israel, July 05, 2024 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX),…
$10 million upfront with up to an additional $20 million upon the exercise in full…
MARKHAM, Ontario, July 05, 2024 (GLOBE NEWSWIRE) -- Extendicare Inc. (“Extendicare” or the “Company”) (TSX:…
NEW YORK, July 4, 2024 /PRNewswire/ -- The global breast tissue expander market size is estimated to…
CHICAGO, July 4, 2024 /PRNewswire/ -- The global microscopy market is poised for significant growth, expected…